Article Information
History
- March 16, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- GJ Connett1,2,*,
- S Maguire3,
- TC Larcombe2,
- N Scanlan2,
- SS Shinde2,
- T Muthukumarana2,
- A Bevan2,
- RH Keogh3 and
- JP Legg1,2
- 1National Institute for Health Research, Southampton respiratory Biomedical Research Centre, University Hospitals Southampton NHS Foundation Trust, Southampton, UK
- 2Southampton Children’s Hospital, University Hospitals Southampton NHS Foundation Trust, Southampton, UK
- 3Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK
- ↵*Correspondence to Professor Gary Connett, University Hospitals Southampton NHS Foundation Trust, Southampton, UK, SO16 6YD. gary.connett{at}uhs.nhs.uk
Posted March 16, 2024.
Real-world impact of Elexacaftor-Tezacaftor-Ivacaftor treatment in young people with Cystic Fibrosis: A longitudinal study
